Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
9 participants
INTERVENTIONAL
2018-03-08
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
99mTc Labelled Affibody SPECT/CT Imaging for Breast Cancer HER2 Characterization
NCT03546478
99mTc-ABH2 SPECT/CT in Breast Cancer
NCT06194565
99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer
NCT05622240
99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients
NCT02742168
HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02
NCT04040686
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
99mTc-RWY SPECT/CT
Volunteers and patients were injected intravenously with 11.1 MBq/kg of 99mTc-RWY in one dose and underwent SPECT/CT scan 30-60 min later.
99mTc-RWY
99mTc-RWY were injected into volunteers and patients before the SPECT/CT scans .
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
99mTc-RWY
99mTc-RWY were injected into volunteers and patients before the SPECT/CT scans .
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index (BMI) at 19 to 25 \[Body mass index = body weight (kg)/ height squared (m2)\];
* Clinical laboratory tests (heart, liver, kidney, blood) indicators are in the normal range or abnormalities without clinical significance;
* Informed written consents were obtained from all 9 subjects before the procedure.
* Patients in suspicion of breast cancer by mammography or ultrasonography, and being able to provide basic information.
Exclution Criteria:
• The investigator judged that it is not suitable for clinical trials based on the overall situation of the volunteers and patients.
25 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China-Japan Union Hospital, Jilin University
OTHER
Sun Yat-sen University
OTHER
Peking University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fan Wang
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University Health Science Center
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
010006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.